Sabine de Ducla
AuthID: R-00G-J2X
1
TITLE: Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial Full Text
AUTHORS: Joseph Gligorov; Dinesh Doval; Jose Bines; Emilio Alba; Paulo Cortes; Jean Yves Pierga; Vineet Gupta; Romulo Costa; Stefanie Srock; Sabine de Ducla; Ulrich Freudensprung; Giorgio Mustacchi;
PUBLISHED: 2014, SOURCE: LANCET ONCOLOGY, VOLUME: 15, ISSUE: 12
AUTHORS: Joseph Gligorov; Dinesh Doval; Jose Bines; Emilio Alba; Paulo Cortes; Jean Yves Pierga; Vineet Gupta; Romulo Costa; Stefanie Srock; Sabine de Ducla; Ulrich Freudensprung; Giorgio Mustacchi;
PUBLISHED: 2014, SOURCE: LANCET ONCOLOGY, VOLUME: 15, ISSUE: 12